|
Chapter 2: Breaking Research and Tech Development in Modern Vaccinology 
-New Thoughts, New Wave, New Methods and New Gateway for Success
|
|
Section 2-1-1: Infectious Immunology, Immunity and Vaccinology
Time: 15:30-17:30, March 23, 2011 (Wednesday)
Place: Room No. 212A, 2F, CNCC
|
|
Chair:
|
Dr. Jo-Anne R. Dillon, Professor & Dean, Vaccine and Infectious Disease Organization, University of Saskatchewan, Canada
|
|
Co-Chair:
|
Dr. Ramaswamy Kalyanasundaram, Professor & Head, University of Illinois, USA
|
|
15:30-15:50
|
Title: Qualitative and Quantitative Analyses of Virtually All Subtypes of Influenza A and B Viral Neuraminidases Using Antibodies Targeting the Universally Conserved Sequences
Dr. Runtao He, Head, Public Health Agency of Canada, Canada
|
|
15:50-16:10
|
Title: High Levels of Maternal IgG anti-Vi Affect Infant’s Antibody Response to Vi Conjugate Vaccine
Dr. Feng-Ying (Kimi) C. Lin, Medical Officer, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, USA
|
|
16:10-16:30
|
Title: Virulence Studies on Cell Division Mutants of Neisseria Gonorrhoeae and Enterohemorrhagic Escherichia Coli
Dr. Jo-Anne R. Dillon, Professor & Dean, Vaccine and Infectious Disease Organization, University of Saskatchewan, Canada
|
|
16:30-16:50
|
Title: SIR2-deficient Leishmania Infantum Induces a Cytokine Profile That Correlates with Protection
Dr. Anabela Cordeiro-da-Silva, Professor & Director, Parasite Disease Group, Institute of Cell and Molecular Biology, Portugal
|
|
16:50-17:10
|
Title: Multivalent Vaccine Approach for Lymphatic Filariasis
Dr. Ramaswamy Kalyanasundaram, Professor & Head, University of Illinois, USA
|
|
17:10-17:30
|
Title: Vitamin D Supplementation for the Prevention of Acute Respiratory Tract Infection: A Randomized Double-blinded Trial among Young Finnish Men
Dr. Ilkka T Laaksi, Researcher, Department of Cell Biology, Medical School, University of Tampere, Finland
|
|
Section 2-1-2: Innate Immunity, Mucosal Immunity and Novel Vaccines
Time: 15:30-17:50, March 23, 2011 (Wednesday)
Place: Room No. 211, 2F, CNCC
|
|
Chair:
|
Dr. Kejian Yang, Vice President, Virology and Vaccine, Biomedical Research Models, Inc., USA
|
|
Co-Chair:
|
Dr. Bernard P Arulanandam, Professor & Associate Dean, Department of Microbiology & Immunology, University of Texas at San Antonio, USA
|
|
15:30-15:50
|
Title: Bacterium-like Particles and Their Role as Adjuvants in Mucosal Vaccines
Dr. Govert J. Schouten, CEO, Mucosis B.V., The Netherlands
|
|
15:50-16:10
|
Title: A Mucosal Vaccination Approach for Herpes Simplex Virus Type-2
Dr. Kejian Yang, Vice President, Virology and Vaccine, Biomedical Research Models, Inc., USA
|
|
16:10-16:30
|
Title: A Mucosal Vaccine against Chlamydia Trachomatis
Dr. Bernard P Arulanandam, Professor & Associate Dean, Department of Microbiology & Immunology, University of Texas at San Antonio, USA
|
|
16:30-16:50
|
Title: Oral Administration of High Molecular Weight Hyaluronan (900 kDa) Controls Immune System Via Toll-like Receptor 4 in the Intestinal Epithelium
Dr. Akira Asari, President, CEO & CSO, Hyaluronan Research Institute (HRI), Japan
|
|
16:50-17:10
|
Title: A Newcastle Disease Virus based Virus-like Particle Chimera Vaccine against Human Respiratory Syncytial Virus
Dr. Matthew R. Murawski, Scientist, Stemcell Technologies, Canada
|
|
17:10-17:30
|
Title: Innate Immune Recognition of Neisseria Meningitidis Capsular Polysaccharides
Dr. Susu M Zughaier, Research Assistant Professor, Emory University School of Medicine, USA
|
|
17:30-17:50
|
Title: The Uniqueness of Mucosa-associated Lymphoid Tissues for the Development of Mucosal Vaccine
Dr. Jun Kunisawa, Lecturer, Institute of Medical Science, The University of Tokyo, Japan
|
Part 2.2: Novel Vaccine Discovery Technology
Section 2-2-1: Bioinformatics, Antigen Design, and Vaccine Development
Time: 13:30-15:30, March 23, 2011 (Wednesday)
Place: Room No. 210B, 2F, CNCC |
|
Chair:
|
Dr. Vidadi M. Yusibov, Executive Director, Fraunhofer USA Center for Molecular Biotechnology, USA
|
|
Co-Chair:
|
Dr. Yongqun ”Oliver” He, Assistant Professor, University of Michigan Medical School, USA
|
|
13:30-13:55
|
Title: VLP-based Vaccine against Malaria
Dr. Vidadi M. Yusibov, Executive Director, Fraunhofer USA Center for Molecular Biotechnology, USA
|
|
13:55-14:20
|
Title: Computational Antibody Vaccine Discovery by Conformational Epitope Prediction and Design of Novel Protein Scaffolds
Dr. Vaikuntanath Samudrala, Associate Professor, Computational Biology Group, University of Washington, USA
|
|
14:20-14:45
|
Title: Systematic Analysis of Vaccine Targets of Bacterial Pathogens Using Vaxign Reverse Vaccinology
Dr. Yongqun ”Oliver” He, Assistant Professor, University of Michigan Medical School, USA
|
|
14:45-15:10
|
Title: Decoding Non-coding Dna Codes: Human Genome Meta-chromosomes Architecture
Dr. Jean-Claude Perez, Individual Researcher, Bordeaux, France
(support from Pr Luc Montagnier FMPRS World AIDS Foundation UNESCO and Jean-rené Fourtou Vivendi Universal chairman)
|
|
15:10-15:30
|
Coffee Break
|
|
Section 2-2-2: DNA Based Vaccines and Technologies
Time: 13:30-14:45, March 23, 2011 (Wednesday)
Place: Room No. 211, 2F, CNCC
|
|
Chair:
|
Dr. Daniel Scherman, Director, Centre National de la Recherche Scientifique (CNRS) / National Scientific Research Center, France
|
|
Co-Chair:
|
Dr. Dinesh K. Singh, Associate Professor, Winston-Salem State University, USA
|
|
13:30-13:55
|
Title: Generation of High-Titer Neutralizing Antibodies against Botulinum Toxins A, B, and E by DNA Electrotransfer
Dr. Daniel Scherman, Director, Centre National de la Recherche Scientifique (CNRS) / National Scientific Research Center, France
|
|
13:55-14:20
|
Title: Human Antibody Engineering for Botulism Prevention and Treatment
Dr. Jianlong Lou, Group Leader, The University of California at San Francisco, USA
|
|
14:20-14:45
|
Title: Use of Recombinant Flagellin to Enhance Mucosal Immunogenicity of a Plasmid SHIV-DNA in Mice
Dr. Dinesh K. Singh, Associate Professor, Winston-Salem State University, USA
|
|
Section 2-2-3: Adjuvants and Vaccine Designs
Time: 08:30-10:55, March 24, 2011 (Thursday)
Place: Room No. 211, 2F, CNCC
|
|
Chair:
|
Dr. Nathalie Garcon, Vice President; Head of Global Adjuvant Center for Vaccines, GlaxoSmithKline Biologicals, Belgium
|
|
Co-Chair:
|
Dr. Wangxue Chen, Senior Research Officer, Institute for Biological Sciences, National Research Council Canada, Canada
|
|
08:30-08:55
|
Title:Adjuvants in Human Vaccines: Selection and Evaluation
Dr. Nathalie Garcon, Vice President; Head of Global Adjuvant Center for Vaccines, GlaxoSmithKline Biologicals, Belgium
|
|
08:55-09:20
|
Title: Potent Novel mRNA Based Vaccines and Adjuvants
Dr. Ingmar Hoerr, CEO & Co-founder, CureVac GmbH, Germany
|
|
09:20-09:45
|
Title: A New Class of Lipidic Immunomodulators that Activate TLR-dependent Cascades and Cytokine Secretion
Dr. Jean-Marie Ruysschaert, Professor, Center of Structural Biology and Bioinformatics, Belgium
|
|
09:45-10:10
|
Title: αGalcer as Adjuvant? Lesson from Chlamydial Research
Dr. Xi Yang, Professor, Department of Medical Microbiology, University of Manitoba, Canada
|
|
10:10-10:30
|
Coffee Break
|
|
10:30-10:55
|
Title: The Potential of 3’,5’-cyclic Diguanylic Acid (c-di-GMP) as an Effective Vaccine Adjuvant
Dr. Wangxue Chen, Senior Research Officer, Institute for Biological Sciences, National Research Council Canada, Canada
|
|
